Clinical Trials Directory

Trials / Unknown

UnknownNCT03644797

Second Molecular Event Identification by Exome Sequencing for Intellectually Disabled Patients Carrying 16p13.11 CNVs

Status
Unknown
Phase
Study type
Observational
Enrollment
18 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

16p13.11 copy number variations are considered as predisposition factors for neurodevelopmental disorders but can be inherited from normal parents. SEESIC aims at identifying seond molecular events by exome sequencing that could modulate the phenotype and explain familial discrepancies.

Conditions

Interventions

TypeNameDescription
GENETICExome sequencingDetection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.

Timeline

Start date
2018-09-01
Primary completion
2018-12-01
Completion
2019-03-01
First posted
2018-08-23
Last updated
2018-08-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03644797. Inclusion in this directory is not an endorsement.